Pruritus in Hemodialysis Patients: Longitudinal Associations With Clinical and Patient-Reported Outcomes.


Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
12 2023
Historique:
received: 31 10 2022
revised: 12 04 2023
accepted: 16 04 2023
medline: 24 11 2023
pubmed: 1 10 2023
entrez: 1 10 2023
Statut: ppublish

Résumé

Cross-sectional studies have reported an association of chronic kidney disease-associated pruritus (CKD-aP) with adverse clinical events and patient-reported outcomes (PROs). We studied the longitudinal associations between changes in CKD-aP and clinical outcomes among patients receiving maintenance hemodialysis. Prospective cohort study. 7,976 hemodialysis recipients across 21 countries in phases 4-6 (2009-2018) of the Dialysis Outcomes and Practice Patterns Study (DOPPS) who had 2 CKD-aP assessments approximately 12 months apart. Exposure status was based on the assessment of pruritis initially and again approximately 1 year later. Four groups were identified, including those with moderate or more severe pruritis only at the initial assessment (resolved), only at the second assessment (incident), at neither assessment (absent), or at both assessments (persistent). Laboratory values and PROs ascertained at the initial assessment of pruritis and 1 year later. Linear mixed model to investigate changes in laboratory values and PROs over the 1-year study period across the 4 exposure groups. 51% of patients had moderate to severe CKD-aP symptoms at either assessment (22% at both). The prevalences of depression, restless sleep, and feeling drained increased over the study period (+13%,+10%, and+14%, respectively) among patients with incident pruritus and decreased (-5%, -8%, and -12%, respectively) among patients with resolved pruritus. Minimal changes in PROs over time were observed for the absent and persistent groups. Changes over time in laboratory values (phosphorus, Kt/V) were not detected for either of these groups. Compared with patients with absent CKD-aP, the adjusted HRs for patients with persistent CKD-aP were 1.29 (95% CI, 1.09-1.53) for all-cause mortality, 1.17 (1.07-1.28) for all-cause hospitalization, and 1.48 (1.26-1.74) for cardiovascular events. No interim evaluation of CKD-aP symptoms between the 2 assessments; potential selection bias from patients who died or were otherwise lost to follow-up before the second assessment. CKD-aP symptoms are chronic, and these findings highlight the potential value of repeated assessment of this symptom using standardized approaches. Future research should systematically investigate potential causes of CKD-aP and options for its effective treatment. Previous research has studied itching and its consequences in hemodialysis recipients only at a single time point. We surveyed 7,976 patients receiving maintenance hemodialysis to assess itching over a period of 1 year. We found that, among those experiencing itching at the initial assessment, more than half had persistent symptoms 1 year later. Those in whom itching developed during follow-up were more likely to experience depression, poor sleep, long recovery times after dialysis, and feeling faint or drained. These patients also rated their quality of life as poorer than those who did not experience itching. These findings emphasize the potential value of clinical detection of itching and the pursuit of effective treatments for patients receiving dialysis experiencing these symptoms.

Identifiants

pubmed: 37777951
pii: S0272-6386(23)00729-1
doi: 10.1053/j.ajkd.2023.04.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

666-676

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Nidhi Sukul (N)

Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; Division of Nephrology, Veterans Affairs Ann Arbor Health System, Ann Arbor, MI. Electronic address: nsukul@med.umich.edu.

Junhui Zhao (J)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Ronald L Pisoni (RL)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Sebastian Walpen (S)

CSL-Vifor, Glattbrugg, Switzerland.

Thilo Schaufler (T)

CSL-Vifor, Glattbrugg, Switzerland.

Elham Asgari (E)

Department of Nephrology, Guy's St Thomas Hospital, London, United Kingdom.

Fitsum Guebre-Egziabher (F)

Department of Nephrology Dialysis Hypertension, Hôpital Edouard Herriot, Hospices Civils de Lyon, Laboratoire de Recherche en Cardiovasculaire, Métabolisme, Diabétologie et Nutrition, Institut National de la Santé et de la Recherche Médicale 1060, University Lyon-1, Lyon, France.

Li Zho (L)

Department of Nephrology, Peking University People's Hospital, Beijing, China.

Mohammed Abdulrahman Al-Ghonaim (M)

Department of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia; College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Kosaku Nitta (K)

Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.

Bruce M Robinson (BM)

Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; Arbor Research Collaborative for Health, Ann Arbor, MI.

Angelo Karaboyas (A)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH